March 31 (Reuters) - Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its ...

Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and ...

Great biotech companies tend to dominate at least one indication. In Biogen's case, that indication is multiple sclerosis. Biogen's Avonex and Tysabri are long-standing blockbuster treatments for ...

S&P 500 component Biogen IDEC Inc reported net income above Wall Street’s expectations for the third quarter. Biogen Idec is a global biotechnology company that meets the rising needs of therapeutic ...

Former Biogen Idec executive Mark Matthews has been appointed to a top sales and marketing post of drug development company Pozen as the company prepares for an expected late 2013 launch of its lead ...

Biogen Idec has partnered with Google X, Google's business unit for long-term “moonshot” projects, to study outside factors that might contribute to the progression of multiple sclerosis (MS), ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Biogen Idec drug Rituxan is the world's most prescribed ...

This year has turned against biotech investors, as the long-awaited correction came on hard in March and April. While conditions seem to have stabilized for the time being, Biogen Idec remains an ...

BOSTON, March 24 (Reuters) - Biogen Idec Inc has acquired an option to license the rights to certain experimental cancer drugs being developed by privately held Aveo Pharmaceuticals Inc. Sign up here.